HOME / NEWS /

2012

J&J’s Janssen Pharmaceuticals and Evotec form strategic diabetes alliance based on HSCI discoveries

July 11, 2012

A portfolio of small molecules and biologics has been licensed by Harvard University and the Howard Hughes Medical Institute from the laboratory of Harvard Stem Cell Institute Co-Director Doug Melton, co-chair of Harvard’s Department of Stem Cell and Regenerative Biology, to the German biotech firm Evotec and international giant Janssen Pharmaceuticals, a Johnson & Johnson company, as the central focus of a new program to pursue treatments and cures for diabetes.

“Our collaboration with Doug Melton’s laboratory has been extremely successful on multiple levels,” said Evotec...

Read more about J&J’s Janssen Pharmaceuticals and Evotec form strategic diabetes alliance based on HSCI discoveries
Cover of 2012 HSCI Annual Report.

2012

April 18, 2012

2012 HSCI call for proposals – P01 pilot grants in human cellular pluripotency

March 12, 2012

Application deadline:  Tuesday, May 1, 2012

The Harvard Stem Cell Institute (HSCI) invites applications for Pilot Grant funding for 2012 under the NIH-funded P01 grant "Dissecting the establishment and regulation of human pluripotency" (PI Alexander Meissner, Harvard Department of Stem Cell and Regenerative Biology). The purpose of this funding program is to provide resources for proof-of-concept studies. These pilot grants are intended to increase our understanding of the basic biology of human pluripotent cells and their utility for translational...

Read more about 2012 HSCI call for proposals – P01 pilot grants in human cellular pluripotency

2012 HSCI call for proposals – Cardiovascular Program pilot grants

March 9, 2012

Application deadline:  Thursday, May 3, 2012

The Harvard Stem Cell Institute (HSCI) Cardiovascular Program invites applications for Pilot Grants for 2012. The purpose of this funding program is to provide resources for research in cardiovascular disease with the goal of developing new therapeutic strategies. As such, a critical component is the translatability of the research project. This may take many forms, and does not require human subjects research; however, thought should be given to how funds will be best used to ultimately bring new therapies or...

Read more about 2012 HSCI call for proposals – Cardiovascular Program pilot grants

2012 HSCI call for proposals – translational program pilot grants

January 26, 2012

The Harvard Stem Cell Institute (HSCI) Translational Program invites applications for Pilot Grant funding for 2012. The purpose of this funding program is to provide resources for proof-of-concept, preclinical research studies ultimately aimed at therapeutic clinical evaluation in humans to treat pediatric and adult disease.  These pilot grants are intended to foster the discovery phase of translational/pre-clinical research, in which possible therapeutic cellular products and their mechanism of action are explored in relevant animal and/or in vitro model systems.... Read more about 2012 HSCI call for proposals – translational program pilot grants